<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02364310</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A00632-45</org_study_id>
    <nct_id>NCT02364310</nct_id>
  </id_info>
  <brief_title>Economic Evaluation of Baroreceptor STIMulation for the Treatment of Resistant HyperTensioN</brief_title>
  <acronym>ESTIM-rHTN</acronym>
  <official_title>Evaluation médico-économique de la Stimulation unilatérale du Sinus Carotidien Dans le Traitement de l'Hypertension artérielle résistante: Essai Multicentrique contrôlé, randomisé, Ouvert Avec évaluation d'efficacité Tensionnelle et de sécurité</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medico-economics assessment (cost-effectiveness) of the unilateral carotid barostimulation&#xD;
      with Barostim NeoTM compared to usual care in patients with resistant hypertension&#xD;
      (multicenter randomized, PROBE trial), followed-up for 12 months, with a lifetime-long&#xD;
      modeling.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 2015</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12th month diurnal SBP (mmHg) measured on ABPM, adjusted on baseline SBP, also used to compute the incremental cost-effective ratio (to identify the extra cost of unilateral carotid barostimulation in BP reduction compared to usual care)</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean SBP 24h on ABPM (mmHg)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean nocturnal SBP on ABPM (mmHg)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean DBP 24h on ABPM (mmHg)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean diurnal DBP on ABPM (mmHg)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean nocturnal DBP on ABPM (mmHg)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Casual SBP (mmHg)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Casual DBP (mmHg)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Casual PP (mmHg)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity (m/s)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Central Pulse Pressure (mmHg)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function and Left ventricular mass on echocardiography (g/m²)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evolution of the kidney function (eGFR - MDRD - ml/min/1.73 m²)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microalbuminuria (mg/mmol creatinine)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antihypertensive regimen (Number of antihypertensive drugs)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol5D (score)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events (number of events)</measure>
    <time_frame>baseline, 6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global cardiovascular risk (scale)</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgery Morbidity</measure>
    <time_frame>1 month</time_frame>
    <description>Clavien Dindo Scale, morbidity 1 month after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cerebrovascular events (number of events)</measure>
    <time_frame>baseline, 6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>kidney events (number of events)</measure>
    <time_frame>baseline, 6 and 12 months</time_frame>
    <description>Comparison with usual care</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cost of unilateral carotid barostimulation including hospital stay</measure>
    <time_frame>participants will be followed for the duration of hospital stay, an expected average of 2 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ICER: difference in cost / difference in office systolic blood pressure (SBP) in mmHg</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>ICER/ICER: difference in cost / difference in QALY (quality-of-life-adjusted survival based on the clinical trial data and the modeling results) for the lifetime modeling</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Budget impact (cost in Euros)</measure>
    <time_frame>4 years</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of outpatient visits for hypertension management in both groups</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Morbidity</measure>
    <time_frame>6 and 12 months</time_frame>
    <description>Tolerance</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Baroreceptor stimulation on top of the best medical care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Baroreceptor stimulation with Barostim Neo TM</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Best medical care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Best medical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Baroreceptor stimulation with Barostim Neo TM</intervention_name>
    <arm_group_label>Baroreceptor stimulation on top of the best medical care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion Criteria:&#xD;
&#xD;
          -  18-85 years old men or women&#xD;
&#xD;
          -  Resistant hypertension on 4 medications incl. thiazide or thiazide-like diuretics at&#xD;
             appropriate doses + spironolactone (unless spironolactone intolerance)&#xD;
&#xD;
          -  Essential hypertension documented (bilan &lt; 2 years old)&#xD;
&#xD;
          -  eGFR ≥ 30 ml/min/1,73 m2&#xD;
&#xD;
          -  No carotid condition associated with a contra-indication for Barostim NeoTM use&#xD;
&#xD;
        Main exclusion Criteria:&#xD;
&#xD;
          -  Patients with documented secondary hypertension, besides Obstructive Sleep Apnea&#xD;
&#xD;
          -  Symptomatic orthostatic hypotension&#xD;
&#xD;
          -  Patient with prior syncope or myocardial infarction, unstable angina pectoris, or&#xD;
             cerebrovascular within 3 months before inclusion&#xD;
&#xD;
          -  Patient with type 1 diabetes mellitus&#xD;
&#xD;
          -  Patient with permanent atrial fibrillation&#xD;
&#xD;
          -  Patient with brachial circumference of ≥ 46cm&#xD;
&#xD;
          -  Patient with BMI&gt;45kg/m2&#xD;
&#xD;
          -  Pregnancy, breastfeeding or planning a pregnancy within 2 years&#xD;
&#xD;
          -  NeoTM implantation anatomic contra-indications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick ROSSIGNOL, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michel AZIZI, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP-HEGP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Arthur Gardiner</name>
      <address>
        <city>Dinard</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospices civils de Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHM</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APHP -Hotel Dieu hospital</name>
      <address>
        <city>Paris</city>
        <zip>75000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GH la Pitié Salpêtrière</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de RENNES</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Pasteur</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>February 2, 2015</study_first_submitted>
  <study_first_submitted_qc>February 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2015</study_first_posted>
  <last_update_submitted>December 15, 2020</last_update_submitted>
  <last_update_submitted_qc>December 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension</keyword>
  <keyword>baroreceptor stimulation</keyword>
  <keyword>Hypertension resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

